Edition:
United States

Alliance Pharma PLC (ALAPH.L)

ALAPH.L on London Stock Exchange

58.00GBp
--
Change (% chg)

-- (--)
Prev Close
58.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
708,531
52-wk High
62.75
52-wk Low
41.78

Chart for

About

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): --
Shares Outstanding(Mil.): 14.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

UPDATE 1-Britain's Alliance Pharma H1 revenue rises on strong sales abroad

Sept 13 British specialty pharmaceutical company Alliance Pharma Plc on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

Sep 13 2017

Britain's Alliance Pharma H1 revenue rises on strong sales abroad

Sept 13 British specialty pharmaceutical company Alliance Pharma Plc on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

Sep 13 2017

BRIEF-Alliance Pharma posts H1 revenue 50.3 mln stg

* INTERIM DIVIDEND UP 10 PERCENT TO 0.443 PENCEPER SHARE​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 13 2017

BRIEF-Alliance Pharma says MHRA disapproves marketing authorisation submission for Diclectin

* ADVISED BY UK'S REGULATOR, MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA), MARKETING AUTHORISATION SUBMISSION FOR DICLECTIN HAS NOT BEEN APPROVED

Jul 28 2017

BRIEF-Alliance Pharma H1 sales up 8 pct

* H1 sales up 8% at GBP 50.3 million versus GBP 46.4 million year ago

Jul 18 2017

Earnings vs. Estimates

No consensus analysis data available.